Review of quetiapine and its clinical applications in schizophrenia

@article{Kasper2000ReviewOQ,
  title={Review of quetiapine and its clinical applications in schizophrenia},
  author={Siegfried Kasper and Franz M{\"u}ller-Spahn},
  journal={Expert Opinion on Pharmacotherapy},
  year={2000},
  volume={1},
  pages={783 - 801}
}
Preclinical studies have shown that quetiapine (Seroquel™, AstraZeneca) is an atypical antipsychotic with many similarities to clozapine. Both placebo-controlled and comparative studies in patients with schizophrenia have demonstrated that quetiapine has long-term efficacy in both positive and negative domains, as well as beneficial effects on affective and cognitive symptoms. Comparative clinical studies confirm that quetiapine is at least as effective as the standard antipsychotics… 

Quetiapine: efficacy and tolerability in schizophrenia

Quetiapine. A review of its use in the management of schizophrenia.

Overall, quetiapine has an excellent risk/benefit profile and is a suitable first-line option for the treatment of schizophrenia, and has benefits in improving cognitive deficits, affective symptoms and aggression/hostility.

Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study

  • J. Hellewell
  • Medicine, Psychology
    International journal of psychiatry in clinical practice
  • 2007
This study provides further evidence for the utility and tolerability of quetiapine, in patients with schizophrenia who had been switched from a previous antipsychotic, following problems with efficacy or tolerability.

Quetiapine: efficacy, tolerability and safety in schizophrenia

The purpose of this article is to critically review the current literature on quetiapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of schizophrenia.

Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics

Results indicate that switching to quetiapine was clinically beneficial for patients with poor efficacy or intolerable side effects on their previous antipsychotic medication.

Quetiapine – efficacy in different domains

  • T. Sharma
  • Psychology, Medicine
    European Neuropsychopharmacology
  • 2001

Quetiapine : A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease

If dosage reduction of antiparkinsonian therapy does not alleviate psychotic symptoms in patients with Parkinson's disease, quetiapine may offer an effective alternative to other atypical antipsychotic agents, without compromising motor function.

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

The results from clinical trials suggest that atypical agents improve negative and affective symptoms, and cognitive functioning more than typical antipsychotics, but that the pattern of effects on these domains, as well as on suicidality, appears to differ.

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

The results indicate that long-term weight changes with quetiapine monotherapy are minimal and potentially beneficial, and do not appear to raise the medical concerns associated with some other atypical agents.
...

References

SHOWING 1-10 OF 92 REFERENCES

Quetiapine : A Review of its Use in Schizophrenia.

Quetiapine should provide a valuable alternative to classical antipsychotic agents in the short term treatment of patients with schizophrenia and its long term effectiveness, position relative to other atypical antipsychotics agents and efficacy in refractory schizophrenia remain to be fully determined.

Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic.

  • P. Meats
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 1997
The preclinical studies predict a low risk of extrapyramidal symptoms, and this is borne out in clinical trials in patients with relapses of moderate or severe schizophrenia, and quetiapine offers the clinician a significant advance over standard antipsychotic drugs.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Quetiapine is an effective antipsychotic with a favorable safety profile and the optimum dose is probably greater than 250 mg/d, which is well tolerated and did not induce extrapyramidal symptoms, sustained elevations of prolactin, or clinically significant changes in hematologic parameters.

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

The quetiapine group had a lower incidence of adverse events than the chlorpromazine group, and a low incidence of treatment‐emergent extrapyramidal symptoms, which support the preclinical profile of quetuapine as an atypical antipsychotic agent.

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

The results indicate that long-term weight changes with quetiapine monotherapy are minimal and potentially beneficial, and do not appear to raise the medical concerns associated with some other atypical agents.

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

Olanzapine seemed to have a risk-versus-benefit advantage in the management of psychotic symptoms, and the differential preclinical profiles of these two drugs were also evident in a controlled, clinical investigation.

Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.

Quetiapine was well tolerated in a nonrandomized study of elderly patients and was associated with improvement in symptoms, including significant improvement in Simpson-Angus Scale total score and CGI-Severity of Illness scores.

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia

Quetiapine is an effective and well tolerated antipsychotic of comparable efficacy to haloperidol and lacks the latter compound's effect on prolactin and EPS.

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
...